ARW’s Q2 beat did not repair the core problem: the market still does not trust this recovery to be durable. EPS came in at $5.45 versus $4.45 consensus, yet shares dropped 8.4% to $203.51. That is not a routine victory lap after a beat; it is a verdict on a cyclical story that needs more than one strong quarter. The rally has outrun the evidence, so this remains a sell-the-proof setup rather than a buy-the-dip moment.
That skepticism matters because Arrow has now beaten EPS estimates in eight straight quarters, which is real execution but also raises the bar. Q1 revenue surged to $9.47 billion, up 39% year over year, after management said sales, margins, and EPS grew significantly. Against that backdrop, another Q2 beat was table stakes. The market wanted evidence that demand could stay strong and that the improvement could flow through the income statement consistently; the immediate selloff says it did not get enough of it.
Valuation is reasonable in isolation, but the stock’s performance has already priced in a substantial recovery. ARW is up 80.0% year to date versus a 30.3% gain for the technology sector. At 12.89 times trailing earnings, Arrow is not expensive by broad market standards, yet it is no longer an undiscovered turnaround. INGM trades at 9.34 times earnings, giving investors a cheaper way to express a distributor-recovery view without paying as much for the story.
The operating profile also leaves little room for a cyclical stumble. Arrow’s net margin is only 2.3%, while operating margin is 3.6%, and free-cash-flow growth is down 103.6%. The TickerSpark Score is 73, with Valuation and Growth both at 90, but Profitability at 50 and Momentum at 60. That mix describes a company with improving earnings and an attractive multiple, not a high-quality compounder that can shrug off a weaker demand stretch.
The bullish reading is not fantasy. Revenue growth is running at 10.5%, EPS growth is 49.9%, and the company has delivered eight consecutive earnings beats. A $1 billion buyback can support per-share results, while analyst coverage still leans constructive with six buys, nine holds, and only two sells. Bulls can reasonably argue that the 8.4% decline is profit-taking after a huge run rather than a rejection of Arrow’s recovery.
That argument still loses on the market’s response. Buybacks can improve per-share math, but they do not prove that component demand, margins, or cash generation are durable. The stock is below its 20-day and 50-day moving averages, and market data shows distribution. When a company beats and still gets marked down sharply, the burden shifts to management to deliver sustained operating proof—not simply another estimate-topping quarter.
For now, we would keep ARW on the watchlist rather than add into the reset. The trigger that would change our mind is a quarter in which the revenue recovery produces expanding margins and a repaired cash-flow trajectory, not merely another EPS beat. Until that happens, INGM’s 9.34x P/E offers the cleaner value setup, while Arrow asks investors to pay for a rebound that its latest reaction suggests is already reflected in the stock.
The technical line to respect is Arrow’s 200-day moving average at $159.98; ARW remains above it, so the long-term trend has not broken. A move back above the 50-day average at $215.72 would improve the setup, but it would not erase the fundamental concern. Position sizing should reflect the thin 2.3% net margin and the unresolved cash-flow weakness.
